This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!
Read Dan on Real Money
CLICK HERE NOW

Dan Rosenblum

Contributor to TheStreet

Dan Rosenblum has been a full-time stock trader since 1999 after leaving a job at a publicly held medical-device company. Rosenblum joined SharkInvesting.com that year and has been the online trading community's resident biotech expert ever since. Rosenblum writes the SharkBiotech.com newsletter, which has outperformed the S&P 500 and the Nasdaq Biotechnology Index every year since its inception in 2006. Rosenblum lives with his wife and kids in Rockland County, New York.

Dan Rosenblum
By This Author:
« Back
Page 1 of 2

Buying Bluebird's Blockbuster Potential at a Discount

By Dan Rosenblum

It's not often an investor gets the opportunity to buy a biotech stock with two blockbuster indications in the pipeline and major catalysts only months away at such a discount.

10:33AM 07/17/14

Why I'm More Confident in Sarepta Than Ever Before

By Dan Rosenblum

Biotech trader Dan Rosenblum believes the recent selloff in Sarepta is a tremendous buying opportunity.

10:06AM 11/04/13

Sarepta: Staying Long and Strong

By Dan Rosenblum

Contributor Dan Rosenblum believes Sarepta's upside potential far outweighs the risk in the stock.

09:25AM 04/25/13

Sarepta Is Undervalued Even Without Eteplirsen Accelerated Approval

By Dan Rosenblum

The exon-skipping drug technology is worth a lot more than just eteplirsen alone.

10:39AM 03/05/13

Insider Buying at Auxilium, Aveo Hints At Big Moves in 2013

By Dan Rosenblum

Insiders at Auxilium and Aveo appear to be betting on turnarounds for both stocks in the next year.

07:30AM 12/20/12

Still Bullish on BioMarin, Lexicon Pharma

By Dan Rosenblum

TheStreet contributor Dan Rosenblum explains why he still likes BioMarin and Lexicon Pharma.

11:28AM 11/07/12

Sunshine Heart: A Promising Treatment for Heart Failure Patients

By Dan Rosenblum

Sunshine's C-Pulse is a heart-assist device for patients who fall between the cracks of current therapy.

08:00AM 11/05/12

Lexicon Pharma: Blockbuster Potential From A Diabetes Drug

By Dan Rosenblum

Lexicons mid-stage diabetes drug blocks the reabsorption of blood sugar.

06:10AM 10/16/12

Biomarin: Four Clinical Trial Events to Watch Before Year End

By Dan Rosenblum

TheStreet contributor Dan Rosenblum explains why Biomarin is a very busy biotech.

07:03AM 09/25/12

Nanosphere: A Low-Risk, High-Growth Diagnostic Stock

By Dan Rosenblum

A hospital-based sepsis test is the launching pad for Nanosphere.

07:13AM 09/18/12

« Back
Page 1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Markets

DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs